Drug Profile
AK 0612
Alternative Names: AK0612Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Ark Biosciences
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Influenza-virus-infections in China
- 28 Aug 2017 Preclinical trials in Influenza virus infections in China (unspecified route) (Arkbiosciences pipeline, August 2017)